CCM2 Antikörper

Produktnummer ABIN1589848

Produktdetails anti-CCM2 Antikörper

Target: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CCM2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunofluorescence (IF)

Verwendungszweck: CCM-2 antibody

Spezifität: Recombinant human CCM2

Produktmerkmale: Chromosomal location: 7p13

Aufreinigung: Protein A purified

Immunogen: Recombinant human CCM2 (ABIN1589765)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western Blot: Use 1-5 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: 0.5X PBS, pH 7.2

Handhabung: Centrifuge vial prior to opening. Avoid repeated freeze-thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu CCM2

Target: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Andere Bezeichnung: CCM-2 (CCM2 Produkte)

Synonyme: C7orf22 antikoerper, OSM antikoerper, malcavernin antikoerper, CCM2 antikoerper, BC029157 antikoerper, TUF2 antikoerper, vtn antikoerper, zgc:110233 antikoerper, CCM2 scaffolding protein antikoerper, cerebral cavernous malformation 2 antikoerper, malcavernin antikoerper, CCM2 antikoerper, Ccm2 antikoerper, LOC100304744 antikoerper, ccm2 antikoerper

Hintergrund: CCM-2, malcavernin, cerebral cavernous malformation 2, OSM, C7orf22, PP10187,Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Familial CCM is caused by mutations in KRIT1 (CCM1) or in malcavernin (CCM2). The roles of the CCM proteins in the pathogenesis of the disorder remain largely unknown. It was shown that the CCM1 gene product, KRIT1, interacts with the CCM2 gene product, malcavernin. Analogous to the established interactions of CCM1 and beta1 integrin with ICAP1, the CCM1/CCM2 association is dependent upon the phosphotyrosine binding (PTB) domain of CCM2. A familial CCM2 missense mutation abrogates the CCM1/CCM2 interaction, suggesting that loss of this interaction may be critical in CCM pathogenesis. CCM2 and ICAP1 bound to CCM1 via their respective PTB domains differentially influence the subcellular localization of CCM1. The data indicate that the genetic heterogeneity observed in familial CCM may reflect mutation of different molecular members of a coordinated signaling complex.

Gen-ID: 83605

NCBI Accession: NM_001029835, NP_001025006

UniProt: Q9BSQ5

Pathways: Cell-Cell Junction Organization